These surprising findings in a group of phenotypically similar patients with ER -positive , endocrine therapy -pretreated , HER2 -negative metastases , are supported by preclinical data showing that sensitivity to 5-fluorouracil is enhanced by deficiencies in chromatin remodeling and homologous recombination genes .